Keyphrases
After Surgery
14%
Age Groups
5%
Androgen Deprivation Therapy
20%
ARAMIS
9%
Bladder Cancer
6%
Breast Cancer
9%
Cancer Mortality
9%
Cancer Treatment
5%
Cancer-related
8%
Cardiovascular Disease
5%
Castration-resistant Prostate Cancer
12%
Clinically Significant Prostate Cancer
6%
Comorbidity
8%
Confidence Interval
22%
Cumulative Incidence
5%
Curative Treatment
5%
Darolutamide
15%
Disease-specific Mortality
6%
Drug Use
6%
Economic Factors
6%
Elderly Patients
9%
Enzalutamide
5%
EPIC-26
12%
Erectile Dysfunction
5%
Europe
11%
European Randomized Study of Screening for Prostate Cancer
9%
Euthyroid
9%
Expanded Prostate Cancer Index Composite
10%
Finland
30%
Finnish Men
5%
Functional Outcome
9%
Geoeconomics
6%
Hazard Ratio
13%
High Risk
5%
High-grade Prostate Cancer
13%
Hypothyroid
7%
Hypothyroidism
14%
International Survey
9%
Laparoscopic Radical Prostatectomy
14%
Levothyroxine
5%
Long Non-coding RNA (LncRNA)
9%
Lower Urinary Tract Symptoms
9%
Lymph Node Metastasis
8%
Lynch Syndrome
9%
Magnetic Resonance Imaging
12%
Metastasis
5%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
18%
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
9%
Non-associated
5%
Non-muscle Invasive Bladder Cancer (NMIBC)
6%
Nonmetastatic Prostate Cancer
6%
Nordic Countries
5%
Oncogenesis
5%
Oncological Outcomes
9%
Operative Treatment
6%
Overall Survival
12%
Persistent Symptoms
5%
Placebo
6%
Population-based Cohort Study
6%
Post-diagnostic Support
5%
Primary Prostate Cancer
6%
Prognostic Factors
11%
Prostate
16%
Prostate Cancer
80%
Prostate Cancer Patients
10%
Prostate Cancer Risk
33%
Prostate Cancer Screening
21%
Prostate Radiotherapy
11%
Prostate-specific Antigen
15%
Prostate-specific Antigen Testing
5%
Prostatectomy
10%
Quality of Life
9%
Radical Prostatectomy
12%
Random Forest Algorithm
6%
Randomized Controlled Trial
12%
Randomized Trial
10%
Recurrence Rate
6%
Reoperation
7%
Risk Factors
5%
Risk of Death
9%
Robot-assisted
9%
Robot-assisted Laparoscopic Radical Prostatectomy
5%
Screening Trials
5%
Sensitivity Analysis
5%
Single Center
5%
Spouses
5%
Statin Use
14%
Statins
8%
Surgical Outcomes
5%
Sweden
5%
Tampere
6%
Three-dimensional (3D)
14%
Tolerability
11%
Total Prostate-specific Antigen
10%
Treatment-related Adverse Events
6%
Tumor
5%
University Hospital
7%
Urinary Incontinence
6%
Visual Analog Scale
6%
Well-being
5%
Medicine and Dentistry
Androgen
6%
Androgen Receptor
7%
Arm
8%
Biopsy Technique
7%
Cancer Cell
8%
Cancer Mortality
21%
Cancer Screening
16%
Cancer Therapy
7%
Carcinogenesis
5%
Castration Resistant Prostate Cancer
5%
Cohort Analysis
8%
Colorectal Carcinoma
6%
Comorbidity
6%
Conservative Treatment
5%
Continence
11%
Diseases
9%
Elderly Patient
9%
Enuresis
5%
Gene Expression
9%
Hazard Ratio
6%
Hereditary Nonpolyposis Colorectal Cancer
9%
Hernioplasty
6%
Hypothyroidism
14%
Levothyroxine
5%
Liotrix
9%
Lymph Node Metastasis
7%
Magnetic Resonance Imaging
15%
Malignant Neoplasm
10%
Metastatic Carcinoma
6%
Neoplasm
10%
Oncology
5%
Overall Survival
6%
Prognostic Factor
10%
Prostate Cancer
100%
Prostate Specific Antigen
17%
Prostatectomy
32%
Quality of Life
6%
Randomized Controlled Trial
14%
Recurrent Disease
7%
Reoperation
7%
Robot-Assisted Prostatectomy
11%
Surgery
6%
Thyroid Gland
20%
Urinary System
9%
Urine Incontinence
5%
Visual Analog Scale
6%